NovaBridge Biosciences(NBP)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Pending next ranking run
This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
NBP Stock Analysis & AI Quality Score
AI stock analysis and institutional research for NovaBridge Biosciences (NBP), a Healthcare sector company. NBP is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q4 2025), NovaBridge Biosciences reports net income of $-30.8M, free cash flow of $-14.6M. Top institutional holders of NBP by reported 13-F value include JANUS HENDERSON GROUP PLC, Hillhouse Capital Advisors, Ltd., MORGAN STANLEY, based on the most recent SEC filings. NBP trades on the Nasdaq exchange and files with the SEC under CIK 1778016. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NBP daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for NovaBridge Biosciences directly from SEC EDGAR.
Net Income
Q4 2025
$-30.8M
Free Cash Flow
Q4 2025
$-14.6M
AI Insight: NBP Financial Trends
NBP's equity declined 95% from $4.6B in Q4 2021 to $231M in Q4 2025 amid accelerating operating losses.
• Equity collapsed from $4,560M in Q4 2021 to $231M in Q4 2025, an 95% decline over four years.
• Operating losses widened from $9M in Q3 2025 to $73M in Q4 2025.
• Net losses increased from $7M in Q3 2025 to $31M in Q4 2025.
⚠ Equity base has shrunk to just 5% of 2021 levels, raising capital adequacy concerns.
⚠ Operating losses accelerated 8x quarter-over-quarter, signaling deteriorating fundamentals.
AI Insight: NBP Ratio Trends
Data is too sparse to identify meaningful trends, with only debt-to-equity and recent negative returns visible.
• Debt-to-equity ratio increased from 0.01 in Q4 2022 to 0.12 in Q4 2023.
• ROE deteriorated sharply from -10.5% in Q3 2025 to -53.3% in Q4 2025.
⚠ Significant data gaps across operating margin, net profit margin, and most return metrics limit trend analysis.
⚠ Negative ROIC of -13.9% in Q3 2025 indicates poor capital allocation efficiency.
Get alerted when NBP's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for NovaBridge Biosciences including:
Top Institutional Holders of NBP
JANUS HENDERSON GROUP PLC
$14.8M6,032,650 shHillhouse Capital Advisors, Ltd.
$14.7M5,980,568 shMORGAN STANLEY
$9.4M3,838,198 shSiren, L.L.C.
$7.4M3,000,000 shAIHC Capital Management Ltd
$5.6M2,262,933 shPoint72 Asset Management, L.P.
$3.4M1,389,403 shCandriam S.C.A.
$2.8M1,132,563 shADAGE CAPITAL PARTNERS GP, L.L.C.
$2.5M1,000,000 shWoodline Partners LP
$1.7M700,000 shBlackRock, Inc.
$1.5M627,496 sh
| Fund | Value | Shares |
|---|---|---|
| JANUS HENDERSON GROUP PLC | $14.8M | 6,032,650 |
| Hillhouse Capital Advisors, Ltd. | $14.7M | 5,980,568 |
| MORGAN STANLEY | $9.4M | 3,838,198 |
| Siren, L.L.C. | $7.4M | 3,000,000 |
| AIHC Capital Management Ltd | $5.6M | 2,262,933 |
| Point72 Asset Management, L.P. | $3.4M | 1,389,403 |
| Candriam S.C.A. | $2.8M | 1,132,563 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $2.5M | 1,000,000 |
| Woodline Partners LP | $1.7M | 700,000 |
| BlackRock, Inc. | $1.5M | 627,496 |
More Healthcare Companies
View all Healthcare →Put NBP on your watchlist
Track score changes the day NovaBridge Biosciences files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is NBP a good stock to buy?
13F Pro's AI-powered analysis of NovaBridge Biosciences (NBP) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for NBP are available on the NBP stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own NBP?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling NBP. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of NovaBridge Biosciences's investment landscape.